Merck presents early-stage interim data for MK-3475, an investigational therapy for the treatment of advanced Melanoma
11 November 2012 | By Merck
Merck announced the presentation of early interim results...
List view / Grid view
News
Novartis data show ACZ885 delivered rapid and strong symptom relief while reducing frequency of attacks in two periodic fever syndromes
11 November 2012 | By Novartis
New data from two Phase II trials of ACZ885...
Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease
10 November 2012 | By Boehringer Ingelheim
Pivotal Phase III interferon-free study being initiated following positive Phase IIb results...
RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants
9 November 2012 | By GlaxoSmithKline
Results from ongoing Phase III clinical trial announced...
Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval
9 November 2012 | By Novo Nordisk
“The positive vote from the Advisory Committee marks an important step..."
RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa®
8 November 2012 | By Boehringer Ingelheim
Pivotal data from the RELY-ABLE® study have provided additional data...
Novartis future growth prospects secured by industry-leading pipeline, with more than 139 projects with 73 new compounds
8 November 2012 | By Novartis
Update on leading R&D pipeline...
Recruitment complete for Trajenta® (linagliptin) cardiovascular outcome study in patients with Type 2 Diabetes
8 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the recruitment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes)1 has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to an active comparator in…
Merck announces FDA acceptance of New Drug Application for Suvorexant, an investigational insomnia medicine
8 November 2012 | By Merck
Merck announced that the NDA for suvorexant has been accepted for standard review...
FOSS releases new version of Vision
8 November 2012 | By FOSS NIRSystems Inc.
FOSS NIRSystems, Inc. has introduced Vision 3.60. Vision is a software package specifically designed for use with the FOSS NIRSystems NIR laboratory & process analyzers...
Merck and Regenstrief Institute Establish Evidence-Based Care Collaboration
8 November 2012 | By Merck
The Regenstrief Institute and Merck have signed a five-year agreement...
Auxilium and Pfizer will conclude agreement on XIAPEX® EU collaboration
7 November 2012 | By Pfizer
Auxilium Pharmaceuticals, Inc., and Pfizer are amending their collaboration agreement...
Novartis drug Signifor® recommended by FDA advisory committee for approval to treat patients with Cushing’s disease
7 November 2012 | By Novartis
Committee votes unanimously in favor of Signifor (pasireotide)...
Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
7 November 2012 | By Novartis
RELAX-AHF study met one of its two primary endpoints...
U.S. Food and Drug Administration approves Pfizer’s XELJANZ® (tofacitinib citrate)
6 November 2012 | By Pfizer
The U.S. FDA has approved XELJANZ®...
